Lovastatin Tablet
Product Images NDC 63629-1464

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lovastatin (NDC 63629-1464). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl636291464)

Label for Lovastatin 20 mg tablet, an oral prescription drug packaged by Bryant Ranch Prepack in Burbank, CA. The label includes a comparison to Mevacor 20 mg tablet by Carlsbad Technology, Inc. It instructs to store the tablets at 20°-25°C (68°-77°F) and warns against use during pregnancy. The package contains 30 tablets and has NDC 63629-1464-1.*

FDA Label Image

Structural Formula (Lov00 0004 01)

Chemical structure of Lovastatin, showing its molecular framework including hydroxy, ketone, and various carbon groups consistent with this active ingredient.*

FDA Label Image

Table I (Lov00 0004 02)

A data table titled 'The Effect of Other Drugs on Lovastatin Exposure When Both Were Co-administered' showing the number of subjects, dosing of coadministered drug or grapefruit juice, dosing of lovastatin, and AUC ratio values comparing lovastatin exposure with and without the coadministered drug for various substances including Gemfibrozil, Itraconazole, Grapefruit Juice (high and low dose), Cyclosporine, and Diltiazem.*

FDA Label Image

Figure 1 (Lov00 0004 03)

A line graph titled 'Acute Major Coronary Events (Primary Endpoint)' showing proportion of participants without event over years of follow-up. Two lines compare Lovastatin with placebo, indicating a 37% risk reduction for Lovastatin with a p-value < 0.001.*

FDA Label Image

Table Vii (Lov00 0005 04)

A data table listing drug interactions associated with increased risk of myopathy or rhabdomyolysis for Lovastatin. It includes interacting agents such as strong CYP3A4 inhibitors, HIV protease inhibitors, gemfibrozil, cyclosporine, danazol, diltiazem, dronedarone, verapamil, amiodarone, and grapefruit juice, along with prescribing recommendations like contraindications, avoidance, or dosage limits.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.